Clinical trials: PD-L1
Advanced Solid Malignancies
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.
- Trial name
- STRONG (NCT03084471)
- Testing
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
- Where
- 79 sites in United States, Canada and 6 more
- Volunteers
- 867 people
- Sponsor
- AstraZeneca
Rectal Cancer
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
This study is being done to look at the safety and response to the investigational drug durvalumab (MEDI4736) following chemo-radiation therapy for patients with MSS stage II to IV rectal cancer.
- Trial name
- NCT03102047
- Testing
- durvalumab
- Where
- 43 sites in United States
- Volunteers
- 45 people
- Sponsor
- NSABP Foundation Inc
Advanced Solid Tumor
A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer
This is a single-arm, open-label, clinical pharmacology study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer.
- Trial name
- NCT05205421
- Testing
- Oncolytic Virus Injection(RT-01)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Advanced Tumors
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of LDP in subjects with advanced malignant tumors.
- Trial name
- NCT03908814
- Testing
- Whole Human Anti-PD-L1 Antibody Injection (LDP)
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
NSCLC Stage IV
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Despite the impressive response rate to PD-1/PD-L1 immune checkpoint inhibitors, resistance inevitably develops in most patients.
- Trial name
- NCT04767009
- Testing
- PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy), SBRT
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Fudan University
Bladder Cancer
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts.
- Trial name
- NCT02108652
- Testing
- Atezolizumab
- Where
- 77 sites in United States, Canada and 6 more
- Volunteers
- 310 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer.
- Trial name
- NCT02826434
- Testing
- PVX-410, Durvalumab, Hiltonol
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Head and Neck Squamous Cell Carcinoma
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with HNSCC who have progressed on or after previous chemotherapy and anti-PD-1/PD-L1 therapy.
- Trial name
- NCT03169764
- Testing
- Avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Ovarian Neoplasms
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
This is a randomized phase II study, aimed at evaluating the efficacy (through progression free survival at 6 months) and safety of 5 different treatments involving atezolizumab, bevacizumab and/or acetylsalicylic acid in…
- Trial name
- NCT02659384
- Testing
- Bevacizumab, atezolizumab, acetylsalicylic acid
- Where
- 12 sites in France, Netherlands and 3 more
- Volunteers
- 122 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed…
- Trial name
- NCT03933449
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Where
- 23 sites in China
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT06780085
- Testing
- Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel
- Where
- 36 sites in United States, Chile and 8 more
- Volunteers
- 96 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Pleural Mesothelioma
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into…
- Trial name
- Immuno-MESODEC (NCT05765084)
- Testing
- Dendritic cell vaccination, Atezolizumab, Platinum/pemetrexed based chemotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 15 people
- Sponsor
- University Hospital, Antwerp
Non Hodgkin Lymphoma, Lymphoma, B-Cell
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
The prognosis of patients with "high-grade B cell lymphoma with cellular myelocytomatosis (MYC) and B cell lymphoma 2 (BCL2) and/or B cell lymphoma 6 (BCL6) rearrangements" (double hit (DH)/triple hit (TH)-HGBL) with…
- Conditions
- Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma, MYC Translocation
- Trial name
- HO152 (NCT03620578)
- Testing
- DA-EPOCH-R followed by Nivolumab
- Where
- 24 sites in Belgium, Netherlands
- Volunteers
- 97 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Solid Tumor
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
Part A (dose-optimization)- to determine the recommended phase 2 dose (RP2D) taking into account dose-limiting toxicity (DLT/s) in Cycle 1, overall safety/tolerability and pharmacokinetic (PK), by optimizing doses of Debio 1143…
- Trial name
- SMARTPLUS-106 (NCT04122625)
- Testing
- Debio 1143, Nivolumab
- Where
- 17 sites in United States, France and 1 more
- Volunteers
- 46 people
- Sponsor
- Debiopharm International SA
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in…
- Trial name
- NCT04165070
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 47 sites in United States, Canada and 8 more
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
- Trial name
- NCT03312842
- Testing
- CS1001
- Where
- 2 sites in China
- Volunteers
- 259 people
- Sponsor
- CStone Pharmaceuticals
Metastatic Triple Negative Breast Cancer
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
The study hypothesise that the combination of carboplatin, gemcitabine, bevacizumab and atezolizumab may be synergistic and improve outcomes for patients with early relapsed TNBC by overcoming mechanisms of immune resistance and…
- Trial name
- BELLA (NCT04739670)
- Testing
- Atezolizumab, Bevacizumab, Gemcitabine
- Where
- 4 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Urothelial Carcinoma
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
This is a phase II trial designed to estimate the activity of single agent tremelimumab in subjects with metastatic urothelial cancer with disease progression despite prior treatment with PD-1/PD-L1 blockade.
- Trial name
- NCT03557918
- Testing
- Tremelimumab
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Matthew Galsky
Extensive-stage Small Cell Lung Cancer
A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Etoposide-cisplatin/ -carboplatin in combination with PD-L1 inhibitor for 4 cycles followed by maintenance therapy with PD-L1 inhibitor is currently the world-wide first-line treatment for extensive-stage small cell lung cancer.
- Trial name
- NCT04636762
- Testing
- Radiation Therapy
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.